ADCv01 added to standard care for newly diagnosed glioblastoma
Part of Brain & nervous system, Cancer clinical trials.
This Phase 2 study tests ADCV01, given “on top of” other standard treatment, for newly diagnosed glioblastoma (grade 4 brain tumor). The goal is to see whether it helps patients live longer and safely manage tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20–75 years old when your brain tumor is surgically removed.
- Your glioblastoma is new (just diagnosed), grade 4, and only one tumor site.
- You must be able to have surgery where no “brain implants” (like drug wafers) are placed, and you agree to preserve tumor tissue to make ADCV01.
- You must be well enough for treatment: stable vital signs, KPS score 70 or higher, and expected life expectancy over 12 weeks.
- Your blood, kidney, and liver tests must fall within set safety limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers a personalized vaccine (DCVax-L) made from your own tumor cells to patients with glioblastoma (a type of brain cancer) who were not able to join a previous study. The vaccine aims to help your immune system fight the cancer.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
This Phase 1/2 trial tests two experimental treatments delivered through a thin catheter placed in the brain for people with newly diagnosed glioblastoma (GBM). The goal is to see whether the treatment can be given safely and whether it may shrink or control the tumor after standard chemotherapy and radiation.
This trial tests an experimental 'vaccine' made from your own immune cells (dendritic cells). The vaccine is designed to train your immune system to attack the brain tumor. It is for people whose glioblastoma has returned or progressed after standard treatment.
This trial tests a personalized vaccine made from your own tumor cells, given after standard treatment (surgery and chemo/radiation) for newly diagnosed glioblastoma. The vaccine aims to train your immune system to fight any remaining cancer cells.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
Hear when a new GBM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.